.jpg?format=webp&width=780)
Researchers focused on the RNA-binding protein Hu antigen R (HuR) as a potential therapeutic target to improve chemotherapy outcomes. They established a docetaxel-resistant TNBC cell line and found that inhibiting HuR with KH-3 enhanced the efficacy of docetaxel. KH-3 decreased the expression of HuR targets and restored docetaxel's effects on inducing apoptosis and cell cycle arrest. The results highlight HuR's role in chemoresistance and support combining HuR inhibitors with chemotherapy for improved efficacy.
Like
Save
Share